Blockchain analytics firm Chainalysis has released a report highlighting a sharp rise in the use of cryptocurrencies among gray market peptide suppliers, as demand for products such as semaglutide soars. The most prominent suppliers are now conducting the bulk of their on-chain activity through Bitcoin and stablecoins.
Inflows Spike to $32 Million, Annual Rate Tops $100 Million
According to the data, total crypto inflows into this gray market segment reached $32 million in the first quarter of 2026, representing a 159% increase from the $12 million recorded in the previous quarter. On an annualized basis, the flow has already exceeded the $100 million mark. The explosive demand is being fueled by sustained interest in medical aesthetics, wellness trends, and the global spotlight on GLP-1 weight-loss medications.
Traditional Payment Barriers Push Suppliers Toward Crypto
The report points out that because peptide products often involve prescription-grade compounds or unregulated substances, mainstream banks and credit card processors typically restrict transactions in this sector. With conventional payment channels narrowing, both suppliers and buyers are migrating to Bitcoin and stablecoins, which operate outside the constraints of centralized financial institutions. This structural shift has created a persistent on-chain money flow within the gray market.
Professionalization of On-Chain Management and the Rise of Stablecoins
Chainalysis further observes that certain leading suppliers are exhibiting increasingly sophisticated on-chain treasury management. Among those with average single deposits exceeding $1,000, the share of stablecoins has notably increased. The firm attributes this trend to an effort to mitigate the volatility inherent in crypto markets, allowing large supply-chain orders to be settled without the risk of major price swings in assets like Bitcoin eroding transaction value.